Cizzle Biotechnology Holdings (LSE:CIZ) Asset Impairment Charge : £0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Cizzle Biotechnology Holdings Asset Impairment Charge?

Cizzle Biotechnology Holdings's Asset Impairment Charge for the six months ended in Dec. 2024 was £0.00 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Dec. 2024 was £0.00 Mil.

Cizzle Biotechnology Holdings Asset Impairment Charge Historical Data

The historical data trend for Cizzle Biotechnology Holdings's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cizzle Biotechnology Holdings Asset Impairment Charge Chart

Cizzle Biotechnology Holdings Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Asset Impairment Charge

Get a 7-Day Free Trial

Cizzle Biotechnology Holdings Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Asset Impairment Charge	Get a 7-Day Free Trial															-	-	-	-	-

Cizzle Biotechnology Holdings Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.00 Mil.

Cizzle Biotechnology Holdings Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Cizzle Biotechnology Holdings's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

Cizzle Biotechnology Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cizzle Biotechnology Holdings PLC (LSE:CIZ) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

E7F0:Germany

Address

C/o SGH Secretaries Limited, 60 Gracechurch Street, 6th Floor, London, GBR, EC3V 0HR

Website

https://www.cizzlebiotechnology.com

Cizzle Biotechnology Holdings PLC is in the early stages of developing a blood test for the early detection of a majority of the different forms of lung cancer. Its proof-of-concept prototype test is based on the ability to detect a stable plasma biomarker, a variant of C1Z1 known as CIZ1B. C1Z1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted C1Z1B variant is correlated with early stage lung cancer.